$2.79
-0.06-2.11%
Last update: Nov 10, 2:38 PM
Ovid Therapeutics Inc
OVIDNASDAQ
Ovid Therapeutics rose 111.1% from $1.35 to $2.85, ahead of the S&P 500's +10.5%. Its worst day was Jan 28 (−14.4%), and its low came Nov 13 at $1.20.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.17 missed the $-0.15 estimate on $132,000.00 revenue (est. $238,228.00).
−2.2% · S&P 500 +0.1%
Ovid Therapeutics shares rose 14.8%, while the S&P 500 rose 1.0%.
Story events cover the past 12 months · Times ET
+14.8% · S&P 500 +1.0%
Ovid Therapeutics shares rose 21.8%, while the S&P 500 rose 0.6%.
+21.8%, the year's best day · S&P 500 +0.6%
Ovid Therapeutics shares fell 14.4%, while the S&P 500 fell 0.0%.
−14.4%, the year's worst day · S&P 500 0.0%
EPS of $0.06 beat the $-0.10 estimate on $718,000.00 revenue (est. $133,560.00).
+14.4%, on 41M shares, the year's heaviest volume · S&P 500 −1.4%
Ovid Therapeutics closed at its highest level of the year, 119.3% above where the year started.
+6.1% · S&P 500 +1.2%
EPS of $-0.12 missed the $-0.11 estimate on $0.00 revenue (est. $60,664.00).
+2.9% · S&P 500 −0.2%
EPS of $-0.08 beat the $-0.10 estimate on $733,000.00 revenue (est. $30,000.00).
+6.9% · S&P 500 +0.7%
Ovid Therapeutics shares rose 14.2%, while the S&P 500 rose 1.7%.
+14.2% · S&P 500 +1.7%
Where it ended: a close of $2.85 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.08, revenue est. $35,048.00).
Nothing in the past 12 months.
All OVID dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OVID and SPY from Benzinga historical bars. Not investment advice.
